KemPharm, Inc. to Report Pharmacokinetic Data From Intranasal Human Abuse Liability Study on Second Quarter Conference Call
August 13, 2015 07:03 ET
|
KemPharm
CORALVILLE, Iowa, Aug. 13, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs,...
KemPharm, Inc. to Report Q2 2015 Results
August 06, 2015 17:20 ET
|
KemPharm
CORALVILLE, Iowa, Aug. 6, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs,...
KemPharm, Inc. to Present at Canaccord Genuity 35th Annual Growth Conference
August 04, 2015 07:03 ET
|
KemPharm
CORALVILLE, Iowa, Aug. 4, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs,...
KemPharm, Inc. Announces Changes to Senior Leadership to Target Strategic Opportunities
June 25, 2015 16:51 ET
|
KemPharm
CORALVILLE, Iowa, June 25, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs,...
KemPharm, Inc. Reports Positive Data From Oral Human Abuse Liability Clinical Trial of KP201/APAP
June 11, 2015 07:03 ET
|
KemPharm
CORALVILLE, Iowa, June 11, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs,...
KemPharm, Inc. Reports Q1 2015 Results
May 27, 2015 16:05 ET
|
KemPharm
Recent Highlights:
Completed pre-NDA meeting for KP201/APAP with FDA on May 20, 2015
Initial public offering closed on April 21, 2015
Appointed David M. Tierney to Board of Directors on...
KemPharm Completes Pre-NDA Meeting With FDA for KP201/APAP
May 21, 2015 09:03 ET
|
KemPharm
CORALVILLE, Iowa, May 21, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs,...
KemPharm's KP201/APAP Featured at the 2015 Abuse Deterrent Formulations Summit
May 19, 2015 16:05 ET
|
KemPharm
CORALVILLE, Iowa, May 19, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary new molecular...
KemPharm, Inc. to Report Q1 2015 Results
May 18, 2015 16:02 ET
|
KemPharm
CORALVILLE, Iowa, May 18, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary new molecular...
KemPharm Announces Pricing of Initial Public Offering
April 15, 2015 21:11 ET
|
KemPharm
CORALVILLE, Iowa, April 15, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc., a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary new molecular entity...